Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The iscom: an immunostimulating system.

B Morein1

  • 1Department of Virology, National Veterinary Institute, Uppsala, Sweden.

Immunology Letters
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Immunostimulating complexes (iscoms) enhance antigen immunogenicity by presenting them on nanoparticles with adjuvants. This approach effectively stimulates antibody and T-cell responses, providing protection against various viral and parasitic infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the humoral immune response to a multicomponent recombinant vaccine against S. aureus in healthy pregnant heifers.

Veterinary journal (London, England : 1997)·2018
Same author

Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.

Veterinary immunology and immunopathology·2014
Same author

The ISCOM: an immunostimulating complex.

Immunology today·2014
Same author

Immune responsiveness in the neonatal period.

Journal of comparative pathology·2007
Same author

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.

Journal of medical virology·2007
Same author

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Clinical and experimental immunology·2004
Same journal

Interleukin-6: A Potential Link in the Pathophysiology of Restless Legs Syndrome.

Immunology letters·2026
Same journal

The dendritic cell identity crisis: why conflicting classifications demand a consensus framework?

Immunology letters·2026
Same journal

The malignancy within: what cancer teaches us about human bonds.

Immunology letters·2026
Same journal

Progranulin enhances complement component 5a-primed neutrophil activation in antineutrophil cytoplasmic antibody-associated vasculitis.

Immunology letters·2026
Same journal

The newly identified role of TRIM72, an E3 ligase, in NINJ1-mediated plasma membrane rupture: focus on its anti-inflammatory function.

Immunology letters·2026
Same journal

The subsets of circulating follicular helper T cells play an important role in the pathogenesis of Autoimmune thyroid diseases.

Immunology letters·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccine Development
  • Nanotechnology

Background:

  • Purified antigens require presentation on particles to be highly immunogenic.
  • Conventional methods for antigen preparation often yield suboptimal immune responses.
  • Nanoparticle-based delivery systems offer a promising strategy for enhancing vaccine efficacy.

Purpose of the Study:

  • To evaluate the immunogenicity and efficacy of immunostimulating complexes (iscoms) as a vaccine delivery system.
  • To assess the ability of iscoms to induce both humoral and cellular immune responses.
  • To demonstrate the protective potential of iscoms against diverse infectious agents.

Main Methods:

  • Antigens were incorporated as multimers onto 40-nm cage-like particles with an adjuvant, forming iscoms.

Related Experiment Videos

  • Iscoms were administered via intranasal or injection routes in animal models (mice, monkeys).
  • Immune responses, including antibody production and cytotoxic T-cell induction, were measured.
  • Efficacy was assessed through challenge infections and tumor formation prevention.

    • Main Results:

    • Iscom-borne antigens induced a 10-fold higher antibody response compared to antigens in micelle form.
    • Intranasal immunization with influenza virus iscoms conferred protection against challenge infection.
    • Iscoms induced potent antibody responses across all Ig classes and isotypes, alongside cytotoxic T cells.
    • Iscoms containing HIV-1 gp160 and measles virus fusion protein elicited antigen-specific cytotoxic T cells and protective immunity.

    Conclusions:

    • Iscoms represent a highly effective platform for enhancing antigen immunogenicity and inducing robust immune responses.
    • Iscoms demonstrate broad applicability in generating protective immunity against viral (influenza, HIV-1, EBV) and parasitic (Trypanosoma cruzi) infections.
    • The nanoparticle structure and built-in adjuvant of iscoms contribute to their potent vaccine-like effects.